Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
October 29, 2025 | HEOR, ISPOR Europe, Market Access, Pricing, US policy, access and pricing, ispor, isporeurope, mfn, most-favoured nation, reimbursement
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10 poster presentations, and the opportunity to try EVID AI, a fast track to literature-based research and evidence synthesis.
With a drinks reception at 5pm on the Monday, the opportunity to grab a free Scottish-themed minifigure, and experts available at the booth at all times, the company warmly invites all attendees to stop by booth 212 for a chat.
HEOR THEATER
MFN Pricing: “More Fun to Navigate” – A European Roadmap to Success
At 12.15pm in Theater 1 on Tuesday 11th November, Tim Wright, EVP, Access & Pricing, Genesis Research Group, will be delivering a presentation on most favored nation (MFN) pricing. Anyone responsible for pricing, market access, early commercial strategy, policy, or HEOR, will find great value in the content.
Most-Favored Nation (MFN) pricing is characterized by uncertainty, particularly regarding how the Administration will steer it through Congress. However, we cannot wait for the legislative process to complete—doing nothing is not an option. Tim Wright, EVP at Genesis Research Group, with 30 years of in-house and consulting experience, will provide a practical walk-through on how to plan for success, including key milestones and challenges along the way.
During the session, Tim will cover essential steps in establishing the US anchor price, including the role of value-based pricing, the importance of setting an early economically justifiable price, and the pros and cons of different US price options. He will then “fly across the Atlantic” to show how these planning steps can positively influence European strategic pricing and, importantly, what options manufacturers have to minimize price erosion risks from subsequent approvals.
By the end of the session, attendees will have:
- A roadmap to help guide them
- through the uncharted territory of Most-Favored Nation pricing.
- A clear understanding of the implications for both biotechs and large pharma.
TRY EVID AI FOR YOURSELF!
Genesis Research Group will also be providing visitors to its booth the opportunity to try EVID AI for themselves. EVID AI is an AI-powered platform for finding, reviewing, and understanding literature-based evidence. If you have too many questions and not enough time, EVID AI allows you to quickly find the most relevant literature, receive AI-generated research summaries, and access to reliable, up-to-date sources.
Visitors will be able to give the platform a try by themselves or they can ask one of Genesis’s evidence synthesis experts for a guided tour.
GRAB A FREE MINIFIGURE!
Visit booth 212 to secure a free minifigure, custom-designed for ISPOR Europe! Choose from a variety of skin tones, hair and facial expressions.
10 SCIENTIFIC CONTRIBUTIONS
Genesis Research Group is proud to have contributed to 10 posters to the conference, including two posters recognized by ISPOR EU as among the top 5% of submissions. See the timetable below or visit ISPOR Europe’s website for full details.
DRINKS RECEPTION
Attendees will also be able to connect with the Genesis Research Group team on an informal basis. Complimentary drinks and canapés will be served from 5pm on Monday 10th November.
Schedule a meeting with the Genesis team
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright's HEOR Theater presentation 'MFN Pricing: More Fun to Navigate – A European Roadmap to Success,' with potentially...
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice...
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice...
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...
Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to...